We established copanlisib (pan-PI3K inhibitor)-resistant B-cell lymphoma and duvelisib (PI3Kδ and -γ inhibitor)-resistant T-cell lymphoma cell lines. The gene discussed is PIK3CB; the disease is B-cell non-Hodgkin lymphoma.